Angle PLC, a liquid biopsy company, has signed a contract with Crescendo Biologics Limited, a UK-based, clinical stage immuno-oncology company with an extensive pipeline of novel, targeted T cell enhancing Humabody therapeutics. Crescendo will use ANGLE’s recently launched Portrait Flex assay in its ongoing Phase 1 trial (NCT04839991) investigating the safety and efficacy of CB307, Crescendo’s first-in-class prostate-specific membrane antigen (PSMA) x CD137 half-life extended bisp...